| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bioventus Inc.$9.78
+0.05 (+0.51%)
D 25Pipeline Score MedTech · Commercial
Market Cap
775.20 M
EPS
0.43
P/E Ratio
22.51 $
Value Trade
11.51 M
SEC Financials
Q1 2026Dilution Risk
Revenue
132.09 M
R&D Expenses
2.47 M
Operating CF
8.93 M
Total Assets
650.54 M
Total Liabilities
416.27 M
Equity
188.90 M
D/E Ratio
12,345
-11.37 %
Week
-5.6 %
1 Month
8.28 %
3 Month
42.11 %
6 Month
-44.83 %
5 Year
-38.54 %
All Time
Cash Data
Cash Position
35.85 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
1.44 M
52 Week Range
5.81 - 11.25
% held by Insiders
31.08 %
% held by Institutions
56.26 %
Enterprise Value
1.07 B
Total Shares
67.72 M
Short %
5.02 %
Float Shares
38.47 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D25
Pipeline Score $84M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 26%
Micro Cap (rank 671 of 905)
Percentile RankBioventus Inc. faces pipeline headwinds (25/100), with $211M risk-adjusted pipeline value, led by PTP-001 in Osteoarthritis, Knee (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTP-001 Monoclonal antibody | Osteoarthritis, Knee | Phase 2 | NCT05100225 | 26% | $211M | ACTIVE NOT_RECRUITING | 210 | STALLED | B (62) | Nov 30, 2022 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BVS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Bioventus Inc. (BVS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BVS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BVSBioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
Bioventus Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Mark Singleton, the company's Senior Vice-President and CFO, will participate in a fireside chat. A live webcast of the event will be available on the company's website, allowing for broader audience engagement.
Read more →BVSBioventus Reports First Quarter Financial Results Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shar
Bioventus Inc. reported its first-quarter financial results for 2026, showing a 7% increase in revenue to $132.1 million. The company achieved a net income of $3.1 million, an improvement from the prior year’s net loss. Non-GAAP earnings rose significantly to $0.15 per diluted share, reflecting strong operational performance. Additionally, Bioventus raised its 2026 financial guidance for Adjusted EPS and Cash from Operations, indicating positive growth momentum.
Read more →BVSBioventus Reports First Quarter Financial Results
Bioventus Inc. reported a strong start to 2026 with a 7% increase in Q1 revenue, totaling $132.1 million. The company achieved positive net income of $3.1 million, a significant turnaround from a loss in the prior year. Bioventus raised its financial guidance for the year, reflecting confidence in continued growth across its product portfolio.
Read more →BVSBioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
Bioventus Inc. will report its financial results for the first quarter of fiscal year 2026 on May 6, 2026. The report will be released before the market opens, followed by a conference call at 8:30 a.m. Eastern Time to discuss the results and provide a business update. A live webcast will also be available for investors.
Read more →BVSBioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Bioventus Inc. reported strong financial results for Q4 and full-year 2025, with a 2.8% increase in revenue and a significant profit turnaround. The company achieved a net income of $14.8 million in Q4, compared to a loss in the previous year. For 2026, Bioventus anticipates continued above-market revenue growth and robust cash generation, reflecting strong demand for its therapies.
Read more →BVSBioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
Bioventus Inc. will announce its financial results for the fourth quarter of fiscal year 2025 on March 5, 2026. The announcement will be made before market opening, followed by a conference call at 8:30 a.m. ET. This call will discuss the results and provide a business update, with a live webcast available for investors.
Read more →BVSBioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
Bioventus Inc. will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Rob Claypoole is scheduled to deliver the presentation at 9:45 a.m. PT. The webcast will be accessible for a limited time on the company's investor website. Bioventus focuses on providing proven, cost-effective health solutions aimed at enhancing patient recovery and quality of life.
Read more →BVSBioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
Bioventus Inc. has announced that its President and CEO, Rob Claypoole, will present at the Piper Sandler Healthcare Conference on December 3, 2025. This event will feature a live webcast of the presentation, along with a question-and-answer session. Bioventus specializes in clinically proven products aimed at promoting active healing across various therapies, including pain management and surgical solutions.
Read more →BVSBioventus Reports Third Quarter Financial Results
Bioventus Inc. reported its financial results for Q3 2025, showcasing an 8.2% organic revenue growth despite a slight decline in reported revenue due to a previous divestiture. The company achieved a net income of $3.2 million, a significant improvement from a loss in the prior year. Adjusted EBITDA also rose by 12.9%, reflecting enhanced profitability and cash flow. However, international revenue faced a decline, highlighting some market challenges.
Read more →BVSBioventus Reports Third Quarter Financial Results Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8% Third quarter GAAP earnings of $0.05 per diluted share increased compar
Bioventus Inc. has reported its third quarter financial results for 2025, revealing a revenue of $138.7 million that is comparable to the previous year, yet slightly down by 0.2% due to a prior divestiture. The company's organic revenue grew by 8.2%, with significant improvements in profitability marked by non-GAAP earnings per share rising 200%. The management expressed confidence in their 2025 objectives, reaffirming their financial guidance amid challenges such as declining revenue in restorative therapies and the impacts of foreign currency and tariffs. Overall, the results reflect growth in key areas of their product portfolio and improved cash flow.
Read more →BVSBioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
Bioventus Inc. will announce its financial results for Q3 of fiscal year 2025 on November 4, 2025. A conference call will be held at 8:30 a.m. ET to discuss these results and provide a business update. The call will be accessible via phone and a live webcast, which will also be archived for later access.
Read more →BVSBioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Bioventus Inc. has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. Mark Singleton, the company's Senior Vice-President and CFO, will engage in a fireside chat on September 10, 2025. The presentation will be available via live webcast and for replay on the company's website, emphasizing Bioventus's commitment to investor engagement.
Read more →BVSBioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
Bioventus Inc. will participate in the Canaccord Genuity 45th Annual Global Growth Conference on August 12, 2025. Rob Claypoole, the company's President and CEO, will engage in a fireside chat, followed by a Q&A session. A live webcast will be available on the company's website, ensuring accessibility for investors and stakeholders.
Read more →BVSBioventus Reports Second Quarter Financial Results Q2 reported revenue of $147.7 million declined 2.4% Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per sha
Bioventus Inc. reported its financial results for the second quarter of 2025, revealing a revenue of $147.7 million, down 2.4% from last year, primarily due to the divestiture of its Advanced Rehabilitation Business. However, organic revenue showed a promising growth of 6.2%, with increased demand in Surgical Solutions and Restorative Therapies. Notably, the company achieved a substantial improvement in diluted earnings per share which reached $0.11, a significant turnaround from a loss in the previous year. Additionally, Bioventus received FDA clearance for two new products aimed at chronic pain management, bolstering its growth outlook.
Read more →BVSBioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
Bioventus Inc. has secured a $400 million Senior Secured Credit Agreement, which includes a $300 million term loan and a $100 million revolving credit facility. This agreement, maturing in 2030, lowers the interest margin and increases liquidity significantly compared to previous arrangements. The funds will be used to repay existing debts, enhancing the company's financial position.
Read more →BVSBioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
Bioventus Inc. has received FDA 510(k) clearances for its TalisMann™ and StimTrial™ products, expanding its Peripheral Nerve Stimulation (PNS) offerings for chronic pain management. This development positions the company to capitalize on a rapidly growing PNS market, projected to exceed $500 million by 2029. A limited commercial release is expected in the third quarter of 2025, with broader rollout plans for early 2026.
Read more →BVSBioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
Bioventus Inc. has announced that it will report its financial results for the second quarter of fiscal year 2025 before market opening on August 6, 2025. A conference call will be held at 8:30 a.m. Eastern Time to discuss these results along with a business update. The company emphasizes its commitment to providing high-quality, evidence-based healing solutions, further highlighting its role in patient care and recovery.
Read more →BVSBioventus Reports First Quarter Financial Results Q1 reported revenue of $123.9 million declined 4.3% Organic* revenue advanced 5.0% First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-yea
Bioventus Inc. reported its financial results for the first quarter of 2025, revealing a revenue decline of 4.3% to $123.9 million compared to the prior year. Despite this downturn, organic revenue showed a positive trend with a 5.0% increase across all business segments. The company reported a net loss of $2.6 million, an improvement from the previous year's $4.9 million loss. Additionally, non-GAAP earnings per share increased by 33%, indicating better underlying performance metrics. The management reiterated its financial guidance for 2025, highlighting an optimistic outlook despite ongoing challenges.
Read more →BVSBioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
Bioventus Inc. has announced that it will report its financial results for the first quarter of fiscal year 2025 on May 6, 2025. The company plans to hold a conference call at 8:30 a.m. Eastern Time to discuss the results and provide updates on its business. Interested parties can access the live webcast on the company's Investor Relations website, which will also be available for replay for one year.
Read more →BVSBioventus Announces Fourth Quarter and Full Year 2024 Financial Results Accelerated fourth quarter sales growth to 13.5% Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bps Fourth qua
Bioventus Inc. reported strong financial results for the fourth quarter and full year 2024, including a 13.5% increase in quarterly revenue reaching $153.6 million. The company's gross margin expanded significantly, and cash from operations rose by 86.3%. Although there was a net loss from continuing operations, the company has provided optimistic financial guidance for 2025, reflecting expected revenue growth and operating margin expansion. Management highlighted sustained double-digit growth in key product segments.
Read more →BVSBioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
Bioventus Inc. has announced that it will report its fourth-quarter financial results for fiscal year 2024 on March 11, 2025, prior to market opening. The company will hold a conference call at 8:30 a.m. Eastern Time to discuss these results and provide a business update. Interested parties can participate in the call or listen to a live webcast available on their website. Bioventus is recognized for its effective healing products and commitment to high-quality standards.
Read more →BVSBioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Bioventus Inc. announced that its CEO, Rob Claypoole, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will be available via live webcast on the company's website and can be accessed until February 15, 2025. Bioventus, known for its innovative healing solutions, aims to assist patients in their recovery and active lifestyles, demonstrating its commitment to quality healthcare.
Read more →BVSBioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Bioventus Inc. has completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners, a private equity firm. This strategic move, announced on October 1, 2024, is aimed at enabling Bioventus to enhance its focus on its core operations. The transaction is expected to generate approximately $20 million in net proceeds, bolstering the company's liquidity. This step is part of Bioventus' broader strategy to improve its market position in the health technology sector.
Read more →BVSBioventus Reports Third Quarter Financial Results Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* Growth Q3 Gross Margin Expanded 200 bps Q3 Cash from Operations of $10.3 million, an Increa
Bioventus Inc. reported a strong performance in its third quarter of 2024, achieving a 15.0% increase in revenue year-over-year, primarily driven by growth in Pain Treatments and Surgical Solutions. Adjusted EBITDA rose by 8.4%, and the company demonstrated improved cash flow with operations generating $10.3 million. However, the company still recorded a net loss from continuing operations, although this was an improvement from the previous year's loss. Additionally, while U.S. sales showed growth, the company faced challenges in its international segment, particularly in Restorative Therapies.
Read more →BVSBioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
Bioventus Inc. announced it will report its financial results for the third quarter of fiscal year 2024 on November 5, 2024, before market opening. The company's management will host a conference call at 8:30 a.m. Eastern Time to discuss the results and provide a business update. Investors can access the conference call via phone or through a live webcast, which will be archived for later viewing on the company's website.
Read more →BVSBioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Bioventus Inc. has finalized an agreement to sell its Advanced Rehabilitation business to Accelmed Partners for $45 million in total cash consideration. Following the divestiture, Bioventus anticipates a reduction of around $50 million in annual revenue and approximately $6 million in Adjusted EBITDA. The sale is expected to close in Q4 2024 and will allow Bioventus to concentrate on its core operations while improving its financial liquidity. Accelmed plans to invest in the Advanced Rehabilitation business to enhance its product offerings.
Read more →BVSBioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
Bioventus Inc. will present at the Canaccord Genuity 44th Annual Global Growth Conference on August 14, 2024, at 9:00 a.m. ET. Mark Singleton, CFO of Bioventus, will engage in a fireside chat followed by a Q&A session. This event underscores the company's commitment to showcasing its innovations in active healing and enhancing visibility among investors and stakeholders.
Read more →BVSBioventus Reports Second Quarter Financial Results Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9% Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bps Cash from Operations of $15.2 million Increase
Bioventus Inc. reported its financial results for the second quarter of 2024, highlighting a 10.3% increase in worldwide revenue driven by strong organic growth of 13.9%. The company expanded its gross margin and raised its full-year financial guidance, reflecting confidence in enhanced revenue growth. However, a significant net loss from continuing operations and an intangible asset impairment charge were also reported. The management remains focused on executing strategic priorities and improving the company’s financial position despite challenges.
Read more →BVSBIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Bioventus Inc. on behalf of long-term stockholders due to a class action complaint filed regarding potential fiduciary breaches by the company’s board. The investigation follows disclosures of significant liquidity issues and misleading financial reporting practices stemming from the company's IPO in February 2021. Bioventus has faced substantial declines in stock value, which has affected investor confidence and led to severe financial implications, including a notable non-cash impairment charge. Current stock prices remain significantly below their initial offering price, further impacting investor interests.
Read more →BVSBioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
Bioventus Inc. has announced it will report its financial results for the second quarter of fiscal year 2024 on August 6, 2024. Prior to market opening, the company will host a conference call to discuss these results and provide a business update. The call will be accessible via phone and a live webcast, which will also be available for replay for a year. Bioventus focuses on innovations for active healing across various medical solutions.
Read more →BVSBioventus Reports First Quarter Financial Results Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities Accelerated First Quarter Revenue Growth by 8.7%,
Bioventus Inc. has reported a strong performance for Q1 2024 with an 8.7% increase in worldwide revenue, totaling $129.5 million, alongside a significant organic growth rate of 15.3%. The company's adjusted EBITDA rose by 33.5% due to enhanced revenue in Pain Treatments and Surgical Solutions. Management has raised the financial guidance for the entire year, showing confidence in continuing growth. However, the company still reported a net loss of $6 million, even as it improved profitability compared to the previous year.
Read more →BVSBioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
Bioventus Inc. has announced it will report its financial results for the first quarter of fiscal year 2024 on May 7, 2024, before market opening. A conference call will follow at 8:30 a.m. Eastern Time to discuss the results and offer a business update. The company's commitment to delivering clinically proven products supports its mission to facilitate active healing.
Read more →BVSBioventus Announces Fourth Quarter and Full Year 2023 Financial Results Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3% Appointed Rob Claypoole as President and Chief Executive Officer, bringing
Bioventus Inc. has released its financial results for the fourth quarter and full year of 2023, demonstrating a positive trend in revenue growth. The company achieved a 7.6% increase in global revenue for the fourth quarter, along with a 14.3% organic growth, largely due to a robust performance in Pain Treatments and Surgical Solutions. Newly appointed CEO Rob Claypoole expressed confidence in the company's strategies and future potential, while the company also provided optimistic financial guidance for 2024 despite reporting a net loss for both the fourth quarter and full year.
Read more →BVSBioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
Bioventus Inc. has announced that it will report its financial results for the fourth quarter of fiscal year 2024 on March 12, 2024. The report will be shared before the market opens, followed by a conference call at 8:30 a.m. Eastern Time to discuss the results. This event aims to keep stakeholders informed about the company's performance and future direction.
Read more →BVSBioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
Bioventus Inc. has announced an amendment to its credit agreement, providing additional financial covenant relief through the third quarter of 2025. This amendment aims to enhance the company's financial and operational flexibility, potentially improving its ability to execute growth initiatives and increase profitability. However, the company will need to revert to existing covenant levels by the fourth quarter of 2025, which poses risks related to future financial reporting and meeting debt covenants.
Read more →BVSBioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Bioventus Inc. announced the issuance of inducement equity awards to Robert Claypoole, who has been appointed as President and Chief Executive Officer. The awards, comprising 375,000 restricted share units and options to purchase 850,000 shares, are set to vest over four years. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Bioventus' commitment to leadership support and growth.
Read more →BVSBioventus Names Robert Claypoole as President and Chief Executive Officer Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth D
Bioventus Inc. has announced the appointment of Robert Claypoole as its new President and CEO, effective January 10, 2024. Claypoole, who succeeds Anthony Bihl, brings over 20 years of experience in the medical device industry, having led significant commercial success at Molnlycke Health Care AB. The Board expressed confidence in his ability to enhance performance and drive growth, following the company's improvements this year. Bioventus reaffirms its financial guidance set earlier in November 2023.
Read more →BVSBioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE for Knee Osteoarthritis
Bioventus Inc. has secured a nationwide contract with Aetna Medicare Advantage plans, allowing over 3 million members access to DUROLANE for knee osteoarthritis treatment starting January 1, 2024. DUROLANE is a single-injection hyaluronic acid treatment that offers pain relief for patients with knee OA. The agreement positions DUROLANE as a preferred option for both Aetna members and physicians, enhancing the company's commitment to providing safe and effective treatment solutions.
Read more →BVSBioventus Reports Third Quarter Financial Results Raises Full Year 2023 Financial Guidance DURHAM, NC
Bioventus Inc. has reported its financial results for Q3 of 2023, indicating a net sales decrease of 6.1% to $120.8 million compared to the same period last year. Despite this decline, the company showed improvements in pain treatments, which saw a revenue increase of 3.1%, and a significant reduction in net loss from $101 million to $8.8 million. Due to better performance and cost management, Bioventus has raised its full-year financial guidance for 2023.
Read more →BVSBioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023
Bioventus Inc. will report its third-quarter financial results for fiscal year 2023 on November 7, 2023. The announcement includes a conference call to be held at 8:30 a.m. Eastern Time to discuss the results and provide a business update. A live webcast will also be available on the company’s Investor Relations page, allowing for easy access to the information.
Read more →BVSBioventus to Present at the Cantor Global Healthcare Conference
Bioventus Inc. has announced that CFO Mark Singleton will participate in a fireside chat at the Cantor Global Healthcare Conference on September 28, 2023. The event will be available for live audio webcast and subsequent replay on the company's website. Bioventus continues to focus on providing innovative healing solutions, promoting a commitment to high quality and evidence-based medicine.
Read more →BVSBioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Bioventus Inc. has announced that Tony Bihl, the interim CEO, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference scheduled for September 13, 2023. This event emphasizes Bioventus's role as a leader in innovations for active healing, showcasing their commitment to delivering effective healthcare products. A live audio webcast will be available, highlighting transparency and accessibility for investors and the public.
Read more →BVSBioventus Reports Second Quarter Financial Results Introduces Full Year 2023 Financial Guidance DURHAM, NC
Bioventus Inc. has reported its second-quarter financial results, showing a net sales decline of 2.3% year-over-year at $137.1 million. The company achieved a significant increase in adjusted EBITDA, up 26.1% compared to the prior year. Notably, the net loss from continuing operations improved from $7.7 million to $4.7 million, reflecting more effective cost management. Despite the challenges of declining gross margins and reduced net sales, the company anticipates a positive outlook for 2023, projecting net sales of $490 million to $505 million.
Read more →BVSBioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
Bioventus Inc. announced that its CFO, Mark Singleton, will present at the Canaccord Genuity Global Growth Conference on August 10, 2023. The presentation will include a live webcast with a subsequent Q&A session, available on the company's website. Bioventus is known for its innovative products in pain treatments and restorative therapies aimed at facilitating quick and safe healing for patients.
Read more →BVSBioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
Bioventus Inc. has announced it will report its financial results for the second quarter of fiscal year 2023 on August 8, 2023, before market opening. The company will hold a conference call at 8:30 a.m. Eastern Time to discuss these results and provide a business update. In addition, a live webcast will be available for investors and stakeholders on the company's website.
Read more →BVSBioventus Completes Divestiture of its Wound Business
Bioventus Inc. has completed the divestiture of its wound business, including TheraSkin and TheraGenesis, to LifeNet Health. This strategic move, which follows an earlier announcement, allows Bioventus to focus more on its core offerings and operations. The company expects to gain approximately $30 million from this transaction, which will assist in debt repayment. Additionally, a Sales Agent Agreement grants LifeNet exclusive rights to sell specific ultrasonic wound products in the U.S. and Canada.
Read more →BVSBioventus Reports First Quarter Financial Results DURHAM, NC
Bioventus Inc. reported its Q1 financial results, showing a net sales increase of 1.5% year-over-year to $119.1 million, despite a significant net loss of $100 million. The company achieved an adjusted EBITDA of $17 million, reflecting a substantial improvement from the previous year, attributed partly to cost-saving initiatives. Challenges included an increase in operating losses and loss per share, leading to a focus on restructuring and divestitures to enhance profitability moving forward.
Read more →BVSBioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
Bioventus Inc. announced the rescheduling of its financial results report for the first quarter of fiscal year 2023 to May 16, 2023, after market close. The company is projecting revenues of approximately $119 million and an Adjusted EBITDA of around $17 million for the quarter ending April 1, 2023. Additionally, Bioventus expects to remain compliant with its financial covenants. A conference call to discuss the results will be held at 5:00 p.m. Eastern Time that day.
Read more →BVSBioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
Bioventus Inc. has announced a delay in reporting its financial results for the first quarter of fiscal year 2023, rescheduling the earnings call to May 16, 2023. The delay is attributed to the complexity of the company's tax structure and its impact on noncontrolling equity calculations. While the company expects revenues of approximately $119 million and an Adjusted EBITDA of about $17 million, there are concerns about the filing process and potential material weaknesses in internal controls.
Read more →BVSBioventus Announces Divestiture of its Wound Business DURHAM, N.C.
Bioventus Inc. has announced the divestiture of its Wound business to LifeNet Health for $85 million, which includes immediate cash at closing and potential earn-out payments. This move is aimed at enhancing liquidity and allowing the company to concentrate on its core business operations. While the divestiture is expected to position the company better financially, it will also lead to a significant reduction in annual revenue and EBITDA. The transaction is anticipated to close shortly before the end of May 2023.
Read more →BVSBioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
Bioventus Inc. announced plans to report its first quarter financial results for fiscal year 2023 on May 11, 2023, before market opening. The management will hold a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update. Investors can participate via a conference call and access a live webcast on the company's Investor Relations section of its website.
Read more →BVSBioventus Announces CEO Leadership Change
Bioventus Inc. has announced the resignation of its CEO, Ken M. Reali, effective immediately, prompting the Board of Directors to initiate a search for a permanent replacement. In the interim, Anthony Bihl, a seasoned executive with over 35 years of experience, has been appointed as the interim CEO. Bihl is expected to leverage his prior experience to stabilize the company and work towards meeting shareholder expectations during this transition period.
Read more →BVSBioventus Reports Fourth Quarter and Full-Year 2022 Financial Results DURHAM, NC
Bioventus Inc. reported its fourth quarter and full-year 2022 financial results, showing a mixed performance. While total net sales for FY 2022 rose by 18.8% to $512.1 million, the company experienced significant losses, culminating in a net loss of $213.4 million for the year. The fourth quarter saw a 3.5% decrease in net sales compared to the previous year, primarily due to challenges in the Pain Treatments segment. However, the company also noted strong growth in its Surgical Solutions vertical and successfully improved its liquidity profile through a recent settlement agreement.
Read more →BVSBioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
Bioventus Inc. has rescheduled its financial results reporting for the fourth quarter of fiscal year 2022 to March 31, 2023, to allow extra time for completing its financial statements. A conference call will follow the report to discuss the results and business updates. The company emphasizes its dedication to providing innovative healing solutions and high quality standards.
Read more →BVSBioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
Bioventus Inc. has announced that it will report financial results for the fourth quarter of fiscal year 2022 on March 30, 2023. A conference call with management will take place at 8:30 a.m. Eastern Time to discuss these results and provide a business update. Interested parties can participate via phone or through a live webcast, which will also be archived for later access. The company emphasizes its mission to support active healing and patient recovery.
Read more →BVSBioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses
Bioventus Inc (NASDAQ: BVS) is facing an investigation initiated by the Portnoy Law Firm on behalf of investors who have incurred losses. Concerns have been raised regarding the company’s financial stability, stemming from issues with a contested invoice and inadequate internal controls over quarterly financial reporting. The stock experienced a significant decline following these revelations. Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss potential legal actions.
Read more →BVSBIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (NASDAQ: BVS)
Bioventus Inc. is currently under a securities class action lawsuit following allegations of material misstatements in its Offering Documents related to its IPO. The lawsuit highlights the company's undisclosed liquidity issues and unsustainable rebate practices, which negatively impacted its financial disclosures. Following a press release about delays and anticipated impairment charges, Bioventus's stock experienced significant declines. A deadline for investors to move as lead plaintiff in the lawsuit is set for March 13, 2023.
Read more →BVSBioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition
Bioventus Inc. announced a Settlement Agreement with former CartiHeal shareholders, which could eliminate up to $350 million of deferred purchase obligations. The agreement allows Bioventus a 30-day period to secure funding to retain CartiHeal. If the funding is not secured, CartiHeal will revert to the sellers. Additionally, Bioventus will pay the sellers $10 million plus expenses as part of the settlement.
Read more →BVSBIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Bioventus Inc. (NASDAQ: BVS)
A securities class action lawsuit has been filed against Bioventus Inc. by Bernstein Liebhard LLP, representing investors who purchased shares between February 11, 2021, and November 21, 2022. The lawsuit alleges violations of the Securities Act, claiming the company made misleading statements regarding its financial condition and operations. Notably, the firm disclosed significant liquidity issues and harmful rebate practices. Following recent announcements about these issues, Bioventus's stock has experienced substantial declines, including a nearly 34% drop in value.
Read more →BVSBIOVENTUS INC. INVESTOR ALERT: Kaplan Fox & Kilshiemer LLP Notifies Bioventus Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP is investigating a class action lawsuit on behalf of Bioventus Inc. investors who acquired shares during the company's initial public offering and the subsequent period. The lawsuit arises following Bioventus' announcement of a substantial potential impairment charge and concerns regarding inadequate internal controls related to revenue recognition. The company's shares experienced a notable decline in value after these disclosures, prompting legal action by investors. A deadline has been set for potential class members to move to serve as lead plaintiffs in the case.
Read more →BVSBioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference
Bioventus Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. CEO Ken Reali will address attendees and participate in a Q&A session. The company is known for its innovations in active healing, offering a range of products for pain treatments, restorative therapies, and surgical solutions. The live webcast of the presentation will be available on Bioventus' website until February 10, 2023.
Read more →BVSBioventus Inc. Shareholder Alert: Kaplan Fox Investigates Potential Securities Fraud (BVS)
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus”) (NASDAQ: BVS). If you would like to discuss our investigation, please contact us by emailing jcampisi@kaplan
Read more →BVSBioventus Issues Revised Third Quarter Results Updates Full-Year 2022 Financial Guidance DURHAM, NC
Bioventus Issues Revised Third Quarter Results Updates Full-Year 2022 Financial Guidance DURHAM, NC - November 21, 2022 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today amended its previously announced financial
Read more →BVSBioventus Inc. Shareholder News: Johnson Fistel Encourages BVS Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS), any of its executive officers, or others violated securities laws by misrepre
Read more →BVSBioventus Inc. Investor Alert: Kaplan Fox Investigates Potential Securities Fraud (BVS)
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus”) (NASDAQ: BVS). If you would like to discuss our investigation, please contact us by emailing jcampisi@kaplan
Read more →BVSDocument Bioventus Files for Extension to File Form 10-Q for the Period Ended
Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022 DURHAM, NC - November 16, 2022 - Bioventus Inc. (Nasdaq BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today the Company has filed a Form 12b-2
Read more →BVSBioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022
DURHAM, N.C., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company has filed a Form 12b-25, Notification of Late Filing for its Quarterly Report on Form 10-Q f
Read more →BVSBioventus Reports Third Quarter Results Updates Full-Year 2022 Financial Guidance DURHAM, NC
Bioventus Reports Third Quarter Results Updates Full-Year 2022 Financial Guidance DURHAM, NC - November 8, 2022 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financial results for the three and nine
Read more →BVSBioventus Inc. Shareholder News: Johnson Fistel Encourages BVS Shareholders with Losses to Contact the Firm Regarding Investigation
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS), any of its executive officers, or others violated securities laws by misrepre
Read more →BVSBioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022
DURHAM, N.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2022 before the market opens
Read more →BVSBioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago
DURHAM, N.C., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present its spine procedural solutions portfolio at the North American Spine Society (NASS) meeting in Chicago, Oct
Read more →BVSBioventus to Present at the Morgan Stanley Global Healthcare Conference
DURHAM, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Globa
Read more →BVSBioventus Reports Second Quarter Results Updates Full-Year 2022 Financial Guidance DURHAM, NC
Bioventus Reports Second Quarter Results Updates Full-Year 2022 Financial Guidance DURHAM, NC - August 11, 2022 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financial results for the three and six m
Read more →BVSBioventus Receives FDA 510(k) Clearance for SonaStar Elite
Innovative New Handpiece Addition to the Nexus Ultrasonic Generator Significantly Expands Company’s Offering in Neurosurgery Ablation Procedures DURHAM, N.C., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in inno
Read more →BVSBioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022
DURHAM, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market opens
Read more →BVSBioventus Completes CartiHeal Acquisition
DURHAM, N.C., July 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal. “We are excited to add CartiHeal to our diverse por
Read more →BVSBioventus Amends CartiHeal Acquisition Structure
DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an amendment to the Option and Equity Purchase Agreement for its pending acquis
Read more →BVSBioventus Reports First Quarter Results Reaffirms Full-Year 2022 Financial Guidance DURHAM, NC
Bioventus Reports First Quarter Results Reaffirms Full-Year 2022 Financial Guidance DURHAM, NC - May 10, 2022 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financial results for three months ended Ap
Read more →BVSBioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial Guidance
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that its subsidiary, Bioventus LLC, has withdrawn its offering of senior notes that was announced on Tues
Read more →BVSBioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE and GELSYN-3 for Knee Osteoarthritis
DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members
Read more →BVSNEWS Bioventus Announces Preliminary First Quarter Net Sales and Adjusted
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA DURHAM, NC - April 26, 2022 - Bioventus Inc. (Nasdaq BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today preliminary financial results for the first qu
Read more →BVSBioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA
DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary financial results for the first quarter ended April 2, 2022. Preliminary First Quarter Net
Read more →BVSBioventus Announces $415 Million Offering of Senior Notes
DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that, subject to market conditions, its subsidiary Bioventus LLC (the “Issuer”) intends to offer for sa
Read more →BVSBioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
DURHAM, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2022 before the market opens
Read more →BVSBioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives
DURHAM, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that TheraSkin coverage now includes three out of the four largest commercial plans in the U.S. along w
Read more →BVSBioventus Announces Inducement Equity to SVP Chief Financial Officer Mark Singleton
DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on April 4, 2022 of previously disclosed inducement equity awards to Mark Singleton in con
Read more →BVSBioventus Exercises Call Option to Acquire CartiHeal
DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has exercised its call option to acquire CartiHeal Ltd., excluding the ownership interest alrea
Read more →BVSBioventus to Present at the Canaccord Genuity Musculoskeletal Conference
DURHAM, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will participate in a fireside chat at the Canaccord Genuity Musculoskeletal Conference on Tu
Read more →BVSBioventus Reports Fourth Quarter and Full Year 2021 Financial Results Introduces Full Year 2022 Financial Guidance DURHAM, NC
Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results Introduces Full Year 2022 Financial Guidance DURHAM, NC - March 10, 2022 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financia
Read more →BVSBioventus Receives 510(k) Clearance for StimRouter Pain Management Device
DURHAM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that the US Food and Drug Administration (FDA) has awarded 510(k) clearance to the next generation StimRouter
Read more →BVSBioventus Appoints Mark Singleton as Chief Financial Officer
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company’s Senior Vice President, Chief Financial Officer and
Read more →BVSBioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022
DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter and fiscal year 2021 before the market open
Read more →BVSBioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue DURHAM, NC
Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue DURHAM, NC - January 11, 2022 - Bioventus Inc. (Nasdaq BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today preliminary revenue results for the fourth qua
Read more →BVSBioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference via webcast on Wednesday, Ja
Read more →BVSBioventus Appoints Michelle McMurry-Heath to Board of Directors
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company’s Board of Directors, effective January
Read more →BVSBioventus Receives US FDA Clearance for BoneScalpel Access™
DURHAM, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s neXus® BoneScalpel® A
Read more →BVSBioventus to Expand Operations and Manufacturing in Memphis
MEMPHIS, Tenn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has signed a lease agreement to double its current operations and manufacturing space and relocate from its current fa
Read more →BVSBioventus Announces Chief Financial Officer Transition Plan
DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today announced that Greg Anglum is transitioning from his role as Senior Vice President and Chief Financial Officer (CF
Read more →BVSBioventus Reports Third Quarter Results Updates Full-Year 2021 Financial Guidance DURHAM, NC
Bioventus Reports Third Quarter Results Updates Full-Year 2021 Financial Guidance DURHAM, NC - November 9, 2021 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financial results for three and nine mont
Read more →BVSBioventus 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA NEWS Bioventus Completes the Acquisition of Misonix DURHAM, NC
Completes the Acquisition DURHAM, NC October 29, 2021 Bioventus Inc. (Nasdaq: BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. ( Misonix ), a provider of minimally invasive therapeutic ultrasoni
Read more →BVSBioventus Completes the Acquisition of Misonix
DURHAM, N.C., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. (“Misonix”), a provider of minimally invasive therapeutic ultrasonic tech
Read more →BVSBioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021
DURHAM, N.C., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Tue
Read more →BVSBioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus DURHAM, NC and FARMINGDALE, NY
Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus DURHAM, NC and FARMINGDALE, NY October 26, 2021 Bioventus Inc. (Nasdaq: BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) ( Mi
Read more →BVSBIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration
DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the “Election Deadline”) for stockholders o
Read more →BVSBioventus Proceeds with Option Structure Agreement with CartiHeal
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has elected to make a $50 million escrow payment pursuant to its Option and Equity Purchase Agreement with CartiHeal Ltd
Read more →BVSBioventus Invests in Trice Medical Minimally Invasive Technologies
DURHAM, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has completed a strategic investment in Trice Medical, Inc., a company focused on developing and commercializing minimal
Read more →BVSBioventus Reports Second Quarter Results Updates Full Year 2021 Financial Guidance DURHAM, NC
Bioventus Reports Second Quarter Results Updates Full Year 2021 Financial Guidance DURHAM, NC - August 10, 2021 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financial results for three and six month
Read more →BVSExecution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this Agreement ) is entered into as of
VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this Agreement ) is entered into as of July 29, 2021, by and between Bioventus Inc., a Delaware corporation ( Parent ), and the persons set forth on Schedule A attached hereto (each, a Stockholder and, collectively
Read more →BVSDocument Bioventus Inc. Reports Preliminary Second Quarter Net Sales Updates Full-Year 2021 Net Sales Guidance DURHAM, NC
Bioventus Inc. Reports Preliminary Second Quarter Net Sales Updates Full-Year 2021 Net Sales Guidance DURHAM, NC - July 29, 2021 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported preliminary financial re
Read more →BVSBioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix
Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower Extremity Enhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical Outcomes Deepens Restorative Therapies Vertical by Adding Regenerative Me
Read more →BVSBioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Quarter Net Sa
Read more →BVSBioventus Management to Present at Canaccord Genuity Growth Conference and Morgan Stanley Virtual Global Healthcare Conference
DURHAM, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12 at 3:30
Read more →BVSBioventus Appoints Mary Kay Ladone to Board of Directors
DURHAM, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Mary Kay Ladone to the Company’s Board of Directors, effective July 15, 2021. In additi
Read more →BVSBioventus Launches OSTEOAMP SELECT Flowable Nationwide
DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of pa
Read more →BVSBioventus Invests in Vaporox
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has completed a minority investment in Vaporox, Inc., a developer of a highly innovative diabetic foot ulcer (“DFU”) wou
Read more →BVSBioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Tu
Read more →BVSBioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In Vitro
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced human placental tissue, prepared as a particulate composition, termed PTP-001, was shown to contain an array of
Read more →BVSBioventus Senior Management to Present at Upcoming Investor Conferences
DURHAM, N.C., May 17, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20 at 8:30
Read more →BVSBioventus Inc. Reports First Quarter Results Updates Full Year 2021 Financial Guidance DURHAM, NC
Bioventus Inc. Reports First Quarter Results Updates Full Year 2021 Financial Guidance DURHAM, NC - May 12, 2021 - Bioventus Inc. (Nasdaq BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financial results for three months ended
Read more →BVSBioventus Announces First Commercial Shipment of the Bioness Integrated Therapy System (BITS) Balance System
VALENCIA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the first commercial shipments of the Bioness Integrated Therapy System (BITS) for Balance. BITS® Balance
Read more →BVSBioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021
DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fiscal year 2021 financial results will be released after the market closes on We
Read more →BVSBioventus Acquires Bioness, Inc.
DURHAM, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc. (“Bioness”), a global leader in neuromodulation and rehabilitation medical devices through i
Read more →BVSBioventus 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA NEWS Bioventus Acquires Bioness, Inc. DURHAM, NC
Bioventus Acquires Bioness, Inc. DURHAM, NC March 30, 2021 Bioventus Inc. (Nasdaq: BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, has acquired Bioness, Inc. ( Bioness ), a global leader in neuromodulation and rehabilitation medical devices
Read more →BVSBioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance DURHAM, NC
Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 DURHAM, NC March 25, 2021 Bioventus Inc. (Nasdaq: BVS) ( Bioventus or the Company ), a global leader in innovations for active healing, today reported financial results for the
Read more →BVSBioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the Treatment of Knee OA
DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalation study of MOTYS (PTP
Read more →BVSBioventus to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 25, 2021
DURHAM, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that fourth quarter and fiscal year 2020 financial results will be released after the market closes on
Read more →BVSBioventus Announces Pricing of Initial Public Offering
DURHAM, N.C., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $13.00 per share. The Company’s Class A common stock
Read more →Competitive Position
How BVS ranks across every disease it competes inCompetitive Position is a premium feature
See how BVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial